Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

Dow Jones

Apr 07

2252 GMT - Pro Medicus this month signaled a willingness to buy back up to 10% of its shares on issue. Citi thinks it ultimately won't be that aggressive with stock purchases. "We do not expect the entire allowance (which would be A$1 billion-plus) to be executed and model A$150 million worth through end FY27," analyst Laura Sutcliffe says. Pro Medicus's share price is down some 64% since its July high. It ended trading before the Easter holiday period at A$118.84. Citi rates Pro Medicus at "buy" with a A$245.00/share price target. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

April 06, 2026 18:52 ET (22:52 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2625418607"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625418607\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625418607?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 06:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625418607","market":"other","top_or_hot":-1,"title":"Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2252 GMT - <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> this month signaled a willingness to buy back up to 10% of its shares on issue. Citi thinks it ultimately won't be that aggressive with stock purchases. \"We do not expect the entire allowance (which would be A$1 billion-plus) to be executed and model A$150 million worth through end FY27,\" analyst Laura Sutcliffe says. <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a>'s share price is down some 64% since its July high. It ended trading before the Easter holiday period at A$118.84. Citi rates <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> at \"buy\" with a A$245.00/share price target. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 06, 2026 18:52 ET (22:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus Unlikely to Complete New Buyback in Full -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-07 06:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  2252 GMT - <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> this month signaled a willingness to buy back up to 10% of its shares on issue. Citi thinks it ultimately won't be that aggressive with stock purchases. \"We do not expect the entire allowance (which would be A$1 billion-plus) to be executed and model A$150 million worth through end FY27,\" analyst Laura Sutcliffe says. <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a>'s share price is down some 64% since its July high. It ended trading before the Easter holiday period at A$118.84. Citi rates <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a> at \"buy\" with a A$245.00/share price target. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 06, 2026 18:52 ET (22:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2625418607","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625418607","pubTimestamp":1775515920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2252 GMT - Pro Medicus this month signaled a willingness to buy back up to 10% of its shares on issue. Citi thinks it ultimately won't be that aggressive with stock purchases. \"We do not expect the entire allowance  to be executed and model A$150 million worth through end FY27,\" analyst Laura Sutcliffe says. Pro Medicus's share price is down some 64% since its July high. It ended trading before the Easter holiday period at A$118.84. Citi rates Pro Medicus at \"buy\" with a A$245.00/share price target. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","PME.AU":"PRO MEDICUS LTD"},"translate_title":"Pro Medicus不太可能全面完成新的回购——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"2252 GMT - Pro Medicus this month signaled a willingness to buy back up to 10% of its shares on issue. Citi thinks it ultimately won't be that aggressive with stock purchases. \"We do not expect the entire allowance (which would be A$1 billion-plus) to be executed and model A$150 million worth through end FY27,\" analyst Laura Sutcliffe says. Pro Medicus's share price is down some 64% since its July high. It ended trading before the Easter holiday period at A$118.84. Citi rates Pro Medicus at \"buy\" with a A$245.00/share price target. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 18:52 ET (22:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}